Drugs facing NCE-1 in 2025

1. List of Amondys 45 drug patents

AMONDYS 45's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48960 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

Do you want to check out AMONDYS 45 patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 25, 2028
New Chemical Entity Exclusivity (NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 2025-02-25

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMONDYS 45 family patents

60

United States

11

European Union

8

Australia

6

Korea, Republic of

5

Israel

5

Japan

4

New Zealand

4

Spain

3

Croatia

3

Denmark

3

Cyprus

3

Poland

3

Slovenia

2

Portugal

2

Hong Kong

2

China

2

Hungary

1

Canada

1

Austria

1

Germany

1

RS

1

Brazil

1

Turkey

1

Lithuania

2. List of Apretude drug patents

APRETUDE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(2 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Do you want to check out APRETUDE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

APRETUDE family patents

32

United States

13

Japan

12

European Union

9

Spain

7

Denmark

7

Slovenia

7

Hungary

6

Korea, Republic of

6

Portugal

6

Poland

5

Norway

5

Lithuania

4

Israel

4

Cyprus

4

Hong Kong

4

Mexico

3

Australia

EA

3

EA

3

Canada

3

Brazil

3

South Africa

3

China

3

Taiwan

2

Luxembourg

2

Netherlands

2

Ukraine

2

Morocco

1

Croatia

1

New Zealand

1

Austria

1

Chile

1

ME

1

Philippines

1

San Marino

1

RS

1

Viet Nam

3. List of Azstarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(9 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

Do you want to check out AZSTARYS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

23

United States

7

Israel

6

Korea, Republic of

5

Japan

4

Canada

4

Mexico

3

Australia

3

China

3

European Union

2

New Zealand

2

Spain

2

Brazil

1

Colombia

1

Croatia

1

Denmark

1

Malaysia

1

Chile

1

Singapore

1

Portugal

1

Ukraine

1

Russia

1

Poland

1

Slovenia

1

Argentina

1

RS

1

South Africa

1

Hungary

1

Lithuania

4. List of Bylvay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416 ALBIREO Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(8 months ago)

US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease
Nov, 2031

(8 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US11365182 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

US11583539 ALBIREO Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Nov, 2041

(18 years from now)

Do you want to check out BYLVAY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

BYLVAY family patents

20

United States

7

European Union

6

Sweden

5

Japan

5

China

5

Hungary

4

Australia

4

Israel

4

Korea, Republic of

4

Canada

4

Denmark

4

Spain

4

Portugal

4

Poland

4

Slovenia

4

Brazil

4

Lithuania

3

Colombia

3

Croatia

3

Singapore

3

United Kingdom

3

Hong Kong

3

Mexico

3

RS

2

Ecuador

2

Peru

2

Malaysia

2

Costa Rica

2

Nicaragua

2

Chile

2

Cyprus

2

Jordan

2

Philippines

2

Russia

2

Norway

2

South Africa

2

Taiwan

1

Iceland

1

New Zealand

1

Uruguay

1

Austria

1

ME

1

Ukraine

1

San Marino

1

Germany

1

Argentina

1

Turkey

5. List of Cabenuva Kit drug patents

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(a month ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 10 months from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(2 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Do you want to check out CABENUVA KIT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

67

United States

35

European Union

23

Japan

21

Norway

21

Hungary

16

Spain

14

Korea, Republic of

13

Denmark

13

Slovenia

12

Australia

12

Lithuania

11

Portugal

11

Poland

11

China

10

Brazil

9

Israel

9

Hong Kong

9

Mexico

EA

8

EA

8

Croatia

8

Canada

8

Cyprus

8

Taiwan

7

Luxembourg

6

New Zealand

6

Ukraine

6

South Africa

AP

5

AP

4

Austria

4

Argentina

3

Netherlands

3

RS

3

Belgium

2

Malaysia

2

Costa Rica

2

Nicaragua

2

Chile

2

ME

2

Singapore

2

Jordan

2

Morocco

1

Panama

1

Egypt

OA

1

OA

1

Uruguay

1

Peru

1

Philippines

1

San Marino

1

Germany

1

Viet Nam

6. List of Cosela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US11529352 G1 THERAP Preservation of immune response during chemotherapy regimens
Jul, 2039

(16 years from now)

Do you want to check out COSELA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2025-02-12

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung can...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

45

United States

14

Japan

11

China

10

European Union

6

Canada

6

Hong Kong

5

Australia

4

Korea, Republic of

4

Mexico

3

Israel

2

Croatia

2

Denmark

2

Spain

2

Cyprus

2

Singapore

2

Portugal

2

Poland

2

Slovenia

2

RS

2

Hungary

2

Lithuania

1

ME

1

Russia

1

San Marino

1

Brazil

7. List of Cytalux drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(10 years from now)

Do you want to check out CYTALUX patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 29, 2026
New Indication (I) Dec 16, 2025
Orphan Drug Exclusivity (ODE) Nov 29, 2028

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 2025-11-29

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CYTALUX family patents

16

United States

5

Japan

4

Australia

3

Canada

3

Mexico

3

China

3

Israel

3

European Union

1

Brazil

EA

1

EA

1

Spain

1

Hong Kong

8. List of Empaveli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(4 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(4 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(4 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(10 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(10 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(10 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods
Apr, 2038

(14 years from now)

Do you want to check out EMPAVELI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 14, 2026
Orphan Drug Exclusivity (ODE) May 14, 2028
M (M) Feb 8, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 2025-05-14

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by ...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

EMPAVELI family patents

43

United States

14

Japan

14

European Union

9

Australia

8

Canada

8

Spain

8

China

6

Israel

5

Denmark

5

Russia

5

Hong Kong

4

Portugal

4

Mexico

4

Brazil

3

Poland

3

Slovenia

2

Croatia

2

Cyprus

2

RS

2

Hungary

2

Lithuania

IB

1

IB

1

Korea, Republic of

1

Austria

1

Norway

9. List of Exkivity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

Do you want to check out EXKIVITY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2026
Orphan Drug Exclusivity (ODE) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 2025-09-15

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE;ORAL

More Information on Dosage

EXKIVITY family patents

6

United States

4

Japan

3

European Union

2

Australia

2

Israel

2

Korea, Republic of

2

New Zealand

2

Chile

2

Singapore

2

Morocco

2

Georgia

2

China

1

Colombia

1

Ecuador

EA

1

EA

1

Croatia

1

Canada

1

Denmark

1

Spain

1

Tunisia

1

Peru

1

Saudi Arabia

1

Costa Rica

1

ME

1

Cyprus

1

Portugal

1

Ukraine

1

Philippines

1

Poland

1

Slovenia

1

Mexico

1

Brazil

1

South Africa

1

RS

1

Cuba

1

Hungary

1

Turkey

1

Lithuania

10. List of Fotivda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2023

(5 months from now)

US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2024

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS NA
Nov, 2039

(16 years from now)

Do you want to check out FOTIVDA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

9

Japan

8

United States

4

European Union

3

Australia

3

Austria

3

Germany

2

Canada

2

Denmark

2

Spain

2

Norway

2

Brazil

EA

1

EA

1

Israel

1

Korea, Republic of

1

Netherlands

1

New Zealand

1

Chile

1

Portugal

1

Russia

1

Poland

1

Hong Kong

1

Mexico

1

China

1

South Africa

1

Belgium

1

Taiwan

11. List of Kerendia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(5 years from now)

Do you want to check out KERENDIA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 9, 2026
M (M) Sep 1, 2025

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 2025-07-09

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

KERENDIA family patents

3

Uruguay

3

United States

2

Malaysia

2

Japan

2

Brazil

2

Hungary

2

Taiwan

2

European Union

1

Panama

1

Colombia

1

Ecuador

1

Australia

1

Israel

1

Croatia

1

Dominican Republic

1

Korea, Republic of

1

Canada

1

Netherlands

1

New Zealand

1

Denmark

1

Honduras

1

Spain

1

Tunisia

1

Peru

1

Saudi Arabia

1

Costa Rica

1

Chile

1

Cyprus

1

Jordan

1

Portugal

1

Ukraine

1

Russia

1

Poland

1

Morocco

1

Hong Kong

1

Germany

1

Mexico

1

Slovenia

1

Guatemala

1

Cuba

1

China

1

Argentina

1

South Africa

1

Lithuania

12. List of Korsuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(4 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

Do you want to check out KORSUVA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: 2025-08-23

Market Authorisation Date: 23 August, 2021

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

KORSUVA family patents

32

United States

3

Korea, Republic of

3

Canada

3

Japan

2

Australia

2

Israel

2

New Zealand

2

Malaysia

2

Russia

2

Mexico

2

China

2

South Africa

2

European Union

1

Denmark

1

Spain

1

Cyprus

1

Portugal

1

Poland

1

Hong Kong

1

Slovenia

1

Brazil

1

Hungary

1

Lithuania

13. List of Leqvio drug patents

LEQVIO's oppositions filed in EPO
LEQVIO Litigations
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(1 year, 2 months ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(1 year, 1 month ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(3 months ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months from now)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(6 months from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(9 months from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(9 months from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(9 months from now)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(11 months from now)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(3 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10590418 NOVARTIS Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Jul, 2022

(10 months ago)

US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months from now)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(4 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(13 years from now)

Do you want to check out LEQVIO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 2025-12-22

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

815

United States

184

European Union

139

Australia

126

Japan

86

Canada

31

Germany

18

Spain

18

Austria

18

China

15

Denmark

13

United Kingdom

13

Mexico

12

Hong Kong

9

Portugal

8

Korea, Republic of

6

Israel

6

Cyprus

EA

5

EA

5

New Zealand

4

South Africa

3

Poland

3

Norway

3

Slovenia

3

Brazil

3

Hungary

2

Russia

2

Lithuania

1

Luxembourg

1

Croatia

IB

1

IB

1

Netherlands

1

Indonesia

1

Chile

1

Singapore

1

Argentina

1

RS

14. List of Livmarli drug patents

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
May, 2031

(7 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(9 years from now)

US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(16 years from now)

US11497745 MIRUM NA
Feb, 2040

(16 years from now)

Do you want to check out LIVMARLI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028
New Patient Population (NPP) Mar 13, 2026

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 2025-09-29

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

LIVMARLI family patents

40

United States

10

Japan

10

European Union

9

Australia

8

Korea, Republic of

7

China

6

Singapore

6

Israel

5

Canada

5

Mexico

5

Brazil

4

South Africa

EA

4

EA

2

Spain

2

Hong Kong

1

Denmark

1

Portugal

1

Poland

15. List of Lumakras drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(14 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Aug, 2040

(17 years from now)

Do you want to check out LUMAKRAS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 2025-05-28

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

LUMAKRAS family patents

14

United States

11

Argentina

7

Japan

5

European Union

4

Australia

4

Israel

3

Korea, Republic of

3

Canada

3

Chile

3

Singapore

3

China

3

Taiwan

2

Colombia

EA

2

EA

2

Uruguay

2

Peru

2

Costa Rica

2

Morocco

2

Brazil

1

Croatia

1

Denmark

1

Spain

1

Saudi Arabia

1

Jordan

1

Portugal

1

Philippines

1

Poland

1

Slovenia

1

Mexico

1

RS

1

Hungary

1

Lithuania

16. List of Lupkynis drug patents

LUPKYNIS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2023

(4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

Do you want to check out LUPKYNIS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

43

United States

22

Japan

10

Canada

9

European Union

7

Australia

7

Korea, Republic of

7

China

5

Israel

4

Croatia

4

Denmark

4

Spain

4

Austria

4

Portugal

4

Russia

4

Poland

4

Norway

4

Germany

4

Brazil

4

South Africa

3

Colombia

3

Ecuador

YU

3

Yugoslavia

3

New Zealand

3

Tunisia

3

Morocco

3

Hong Kong

3

Mexico

3

Taiwan

2

Uruguay

2

Malaysia

2

ME

2

Slovenia

2

Argentina

IB

1

IB

1

Chile

1

Singapore

1

Belgium

1

Lithuania

17. List of Lybalvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(2 years from now)

US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241425 ALKERMES INC Composition for treating mental illness
Aug, 2031

(8 years from now)

US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11351166 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(8 years from now)

Do you want to check out LYBALVI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 2025-05-28

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administ...

Dosage: TABLET;ORAL

More Information on Dosage

LYBALVI family patents

26

United States

6

Australia

6

Japan

6

European Union

3

Canada

3

Denmark

3

Spain

3

Portugal

3

Poland

3

Slovenia

2

Croatia

2

New Zealand

2

Cyprus

2

Russia

2

RS

2

Hungary

2

Turkey

2

Lithuania

1

Israel

1

Korea, Republic of

1

Austria

1

ME

1

Norway

1

Mexico

1

China

1

Brazil

18. List of Nextstellis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(1 year, 8 months from now)

Do you want to check out NEXTSTELLIS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 2025-04-15

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

17

European Union

14

Netherlands

9

Canada

9

United States

7

Spain

7

Germany

6

Denmark

6

Austria

6

Portugal

1

Ecuador

1

Luxembourg

1

Australia

EA

1

EA

1

Israel

1

Korea, Republic of

YU

1

Yugoslavia

1

New Zealand

1

Costa Rica

1

ME

1

Cyprus

1

Ukraine

1

Poland

1

Japan

1

Norway

1

Hong Kong

1

Mexico

1

Brazil

1

China

1

South Africa

1

Hungary

1

Belgium

1

Turkey

19. List of Nulibry drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 SENTYNL THERAPS INC Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Jan, 2025

(1 year, 7 months from now)

Do you want to check out NULIBRY patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026
M (M) Oct 27, 2025

Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient

NCE-1 date: 2025-02-26

Market Authorisation Date: 26 February, 2021

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

NULIBRY family patents

3

Germany

1

Canada

1

Cyprus

1

Slovenia

1

Denmark

1

Portugal

1

Spain

1

Poland

1

United States

1

European Union

20. List of Pepaxto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2023

(22 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(8 years from now)

US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide
Apr, 2032

(8 years from now)

US11344622 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(8 years from now)

US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(8 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(8 years from now)

Do you want to check out PEPAXTO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: 2025-02-26

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received a...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

PEPAXTO family patents

15

United States

7

European Union

6

Korea, Republic of

5

Denmark

5

Sweden

5

Spain

5

Portugal

4

Israel

4

Croatia

4

Canada

4

China

4

RS

4

Lithuania

3

Australia

3

Poland

3

Japan

3

Slovenia

3

Hungary

2

New Zealand

2

Cyprus

2

Russia

2

Hong Kong

2

Mexico

2

Brazil

2

South Africa

1

Austria

1

Germany

21. List of Ponvory drug patents

PONVORY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(1 year, 5 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(1 year, 5 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(2 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(12 years from now)

Do you want to check out PONVORY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

18

United States

12

European Union

8

Korea, Republic of

7

Japan

5

Australia

5

Israel

4

Canada

4

China

EA

3

EA

3

Croatia

3

Denmark

3

Spain

3

Malaysia

3

Chile

3

Portugal

3

Poland

3

Morocco

3

Slovenia

3

Mexico

3

Brazil

3

South Africa

3

Taiwan

2

New Zealand

2

Cyprus

2

Singapore

2

Ukraine

2

Russia

2

Philippines

2

Norway

2

Hong Kong

2

Argentina

2

Hungary

2

Lithuania

IB

1

IB

1

Netherlands

1

Saudi Arabia

1

Austria

1

United Kingdom

1

Germany

1

RS

22. List of Pylarify drug patents

PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(4 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(6 years from now)

US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(7 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(14 years from now)

Do you want to check out PYLARIFY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 2025-05-26

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PYLARIFY family patents

28

United States

10

Japan

9

European Union

6

Spain

6

China

5

Poland

5

Hungary

4

Canada

4

Portugal

3

Denmark

3

Hong Kong

3

Slovenia

2

Australia

2

Croatia

2

Korea, Republic of

2

Cyprus

2

Lithuania

1

Singapore

1

Russia

1

Brazil

1

Taiwan

23. List of Qelbree drug patents

QELBREE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458143 SUPERNUS PHARMS NA
Sep, 2029

(6 years from now)

US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(6 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

Do you want to check out QELBREE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 2, 2026
New Patient Population (NPP) Apr 29, 2025

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: U-727: for the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

QELBREE family patents

14

United States

4

Australia

3

Japan

2

Canada

2

European Union

1

Mexico

1

Spain

24. List of Qulipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(11 years from now)

Do you want to check out QULIPTA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 2025-09-28

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

QULIPTA family patents

36

United States

9

European Union

4

Australia

4

China

3

Korea, Republic of

3

Canada

3

Japan

3

Hong Kong

3

Taiwan

2

Israel

2

Croatia

2

Denmark

2

Spain

2

ME

2

Cyprus

2

Singapore

2

Portugal

2

Russia

2

Poland

2

Slovenia

2

Mexico

2

RS

1

Colombia

1

Ecuador

EA

1

EA

1

Dominican Republic

1

New Zealand

1

Tunisia

1

Peru

1

Malaysia

1

Saudi Arabia

1

Costa Rica

1

Nicaragua

1

Chile

1

Ukraine

1

Morocco

1

Guatemala

1

Argentina

1

Brazil

1

Hungary

1

Lithuania

25. List of Rezurock drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8357693 KADMON PHARMS LLC Pharmacokinetically improved compounds
Oct, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183931 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US9815820 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US10696660 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(10 years from now)

US11311541 KADMON PHARMS LLC Treatment of GVHD
Apr, 2035

(11 years from now)

Do you want to check out REZUROCK patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2026
Orphan Drug Exclusivity (ODE) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 2025-07-16

Market Authorisation Date: 16 July, 2021

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chr...

Dosage: TABLET;ORAL

More Information on Dosage

REZUROCK family patents

23

United States

6

China

4

Japan

3

Canada

3

European Union

EA

2

EA

2

Spain

1

Ecuador

1

Australia

1

Croatia

1

Korea, Republic of